Market revenue in 2023 | USD 9,892.1 million |
Market revenue in 2030 | USD 12,562.5 million |
Growth rate | 3.5% (CAGR from 2023 to 2030) |
Largest segment | Stimulants |
Fastest growing segment | Non-stimulants |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stimulants, Non-stimulants |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.84% in 2023. Horizon Databook has segmented the U.S. attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is a major market for ADHD, owing to factors such as high awareness among healthcare professionals about drugs available for treating ADHD and rise in disease prevalence. Increasing the use of additives and preservatives in children's diets can increase hyperactivity & impulsive behavior in children.
Product launches and collaborations are other factors boosting market growth. For example, in April 2021, the U.S. FDA approved Supernus Pharmaceuticals' Qelbree for the treatment of children and adolescent patients aged 6 to 17 years. It was the first noncontrolled, nonstimulant drug option in a decade to be included in the ADHD treatment portfolio.
Product launches and collaborations are other factors boosting market growth. For example, in April 2021, the U.S. FDA approved Supernus Pharmaceuticals' Qelbree for the treatment of children and adolescent patients aged 6 to 17 years. It was the first noncontrolled, nonstimulant drug option in a decade to be included in the ADHD treatment portfolio.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. attention deficit hyperactivity disorder market , including forecasts for subscribers. This country databook contains high-level insights into U.S. attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account